Literature DB >> 1930031

Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis.

S M Garland1, J R Fliegner.   

Abstract

At the Royal Women's Hospital, Melbourne over an 8-year period (1981-1988) all public antenatal patients were screened at 32 weeks' gestation for group B streptococcus (GBS). In a total of 30,197 livebirths there were no early onset neonatal GBS infections in infants of treated asymptomatic carrier mothers. By contrast there were 27 infections with 8 deaths in an unscreened control group of private patients (total livebirths 26,915). It is recommended that GBS screening occur antenatally at 28 weeks and that intrapartum chemoprophylaxis be offered at least to those carriers with obstetric risk factors.

Entities:  

Mesh：

Year:  1991        PMID： 1930031     DOI： 10.1111/j.1479-828x.1991.tb01797.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN： 0004-8666            Impact factor:   2.100


  18 in total

1.  Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Mortality from early onset group B streptococcal infection in the United Kingdom.

Authors:  N Embleton; U Wariyar; E Hey
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

3.  Prevention of group B streptococcal infection in newborns. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

4.  The Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of neonatal group B streptococcal infections in Canada.

Authors:  H D Davies; J Leblanc; R Bortolussi; A McGeer
Journal:  Paediatr Child Health       Date:  1999-05       Impact factor: 2.253

Review 5.  The risks and benefits of antimicrobial therapy in pregnancy.

Authors:  S M Garland; M A O'Reilly
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 6.  Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.

Authors:  Joyce M Koenig; William J Keenan
Journal:  Pediatr Clin North Am       Date:  2009-06       Impact factor: 3.278

7.  Efficacy of a universal screening program for the prevention of neonatal group B streptococcal disease.

Authors:  M de Cueto; M J Sánchez; L Moltó; J A Miranda; A J Herruzo; A Ruiz-Bravo; M de la Rosa-Fraile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

Review 8.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 9.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

10.  In vitro resistance to macrolides and clindamycin by Group B Streptococcus isolated from pregnant and nonpregnant women.

Authors:  Antonietta Lambiase; Annalisa Agangi; Mariassunta Del Pezzo; Filomena Quaglia; Antonio Testa; Fabio Rossano; Pasquale Martinelli; Maria Rosaria Catania
Journal:  Infect Dis Obstet Gynecol       Date:  2012-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.